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A prototype, real-time reverse-transcription PCR assay, based on MultiCode-RTx technology, quantifying
hepatitis C virus (HCV) RNA by targeting the HCV 3 untranslated region demonstrated linearity over 7 logs,
with a good correlation between the quantitative results of this assay and the results of two commercially
available comparator assays for 466 clinical specimens comprising all six HCV genotypes.
Current commercially available laboratory methods for the
detection and quantification of hepatitis C virus (HCV) RNA
in clinical specimens include transcription-mediated amplifica-
tion, branched-DNA, and real-time PCR (1, 2, 4–6, 9, 10, 13,
18). All of these methods target the highly conserved HCV 5
untranslated region (UTR) rather than the similarly conserved
3 UTR, which was not recognized during initial characteriza-
tion of the HCV genome (3, 7) but was subsequently identified
(8). Recently, a prototype real-time PCR assay based on Multi-
Code-RTx PCR technology (i.e., the RTx assay; EraGen Bio-
sciences, Inc., Madison, WI) (11, 15–17) and targeting the
HCV 3 UTR was developed for HCV detection and quanti-
fication. Herein, we report the results of the initial analytical
evaluation of this novel RTx assay along with preliminary cor-
relation studies comparing the RTx assay to the Versant HCV
RNA 3.0 assay (the bDNA assay; Siemens Healthcare Diag-
nostics, Inc., Tarrytown, NY) and a laboratory-developed assay
based on the TaqMan HCV analyte-specific reagent (the Taq-
Man assay; Roche Molecular Systems, Inc.) (1, 2, 4, 6, 9).
For the initial analytical studies, individual RTx assay reac-
tion mixtures contained 0.5 U/l Moloney murine leukemia
virus reverse transcriptase and 1 Titanium Taq DNA poly-
merase (Clontech, Mountain View, CA) in 1 ISOlution 1482
buffer (EraGen Biosciences, Inc.) along with primer sets to
specifically amplify two targets. The first primer set, labeled
with 6-carboxyfluorescein, targeted a 48-bp region of the HCV
3 UTR, while the second primer pair, labeled with hexachlo-
rofluorescein, targeted a 72-bp segment of an RNA internal
control sequence added at 250 copies/reaction. Thermal cy-
cling was performed with an ABI Prism 7700 sequence detec-
tion system (Applied Biosystems, Foster City, CA), with the
following parameters: 15 min at 50°C, 2 min at 95°C, followed
by 50 cycles of 95°C for 5 s, 58°C for 10 s, and 72°C for 20 s.
Following PCR, a 5-min thermal ramp (60°C to 95°C) was
performed to determine melting point (Tm) values of the am-
plified products.
An in vitro RNA transcript containing both the HCV 5
UTR and the 3 UTR was used to prepare a series of RTx
assay reaction mixtures containing 10-fold dilutions of this
transcript ranging from 108 to 101 copies/reaction. Data ob-
tained from RTx assay testing of these analytical samples in
quadruplicate were exported to MultiCode-RTx analysis soft-
ware (EraGen Biosciences, Inc.) for further analysis. The pres-
ence of HCV RNA was confirmed by a 6-carboxyfluorescein
amplification curve with a Tm of 80.4  1.0°C occurring within
50 cycles and crossing a cycle threshold (CT) set at 10 times the
standard deviation (SD) of the baseline noise. Results showed
that the RTx assay was linear over 7 logs (Fig. 1) and sensitive
enough to detect two of four replicates at 10 copies/reaction.
For all subsequent studies, the RTx assay was modified to
include two manual nucleic acid extraction procedures, both of
which incorporate the use of an unrelated extractable sample
processing reference (SPR; EraGen Biosciences, Inc.) that
contains the internal control sequence used in the analytical
studies. In a quantitative small-volume RTx protocol used for
initial testing of specimens, 3.5 l of SPR (1,000 copies/l) was
added to 136.5 l of specimen and processed by use of the
QIAamp viral RNA minikit (Qiagen, Inc., Valencia, CA) ac-
cording to the manufacturer’s instructions, with a final elution
volume of 70 l. In a qualitative large-volume RTx protocol
used for testing specimens yielding discordant viral load (VL)
results, 3 l of SPR was added to 497 l of specimen and
processed by use of the QIAamp MinElute virus vacuum kit
(Qiagen, Inc.) according to the manufacturer’s instructions,
with a final elution volume of 60 l. The small-volume RTx
* Corresponding author. Mailing address: EraGen Biosciences, Inc.,
918 Deming Way, Madison, WI 53717. Phone: (608) 662-9000. Fax:
(608) 662-9003. E-mail: sjohnson@eragen.com.
 Published ahead of print on 17 June 2009.
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assay reaction mixture (25 l) contained 5 l of eluate, while
the large-volume RTx assay reaction mixture (100 l) con-
tained 50 l of eluate.
To create a standard curve for RTx assay HCV VL deter-
mination, serial fivefold dilutions (neat to 1:3,125) of a high-
titer HCV RNA-positive serum specimen were prepared in
HCV RNA-negative serum and tested in replicate (20 reac-
tions/dilution) by the small-volume RTx protocol. The stan-
dard curve was then calibrated to WHO Second International
HCV standard 96/798 by correlating the known HCV VL and
experimentally determined mean CT value from 36 replicate
amplifications of a single concentration of the standard. The
resulting equation was used to determine the HCV VLs (in
IU/ml) in clinical specimens based on the mean CT of duplicate
RTx assay reactions.
Amplification equivalency among HCV genotypes was ini-
tially studied by using a 13-member worldwide HCV perfor-
mance panel (WWHV302) (Boston Biomedica, Inc., West
Bridgewater, MA), which was tested in triplicate by the quan-
titative small-volume RTx protocol. The small-volume RTx
assay VL results were compared to VL data (provided in the
WWHV302 product insert) from the bDNA assay and the
Cobas Amplicor HCV Monitor test, version 2.0 (CAM test;
Roche Molecular Systems, Inc., Branchburg, NJ).
Frozen aliquots of 466 leftover clinical specimens submitted
for routine HCV VL testing at three different clinical labora-
tories between January 2006 and January 2008 were deidenti-
fied, handled in a blind manner, and sent to EraGen Bio-
sciences, Inc., for testing by the RTx assay. These specimens
included 200 serum and plasma specimens from Dynacare
Laboratories, Milwaukee, WI; 110 serum specimens from the
Mayo Clinic, Rochester, MN; and 156 plasma specimens from
the Washington University School of Medicine, St. Louis, MO.
The 200 clinical specimens from Dynacare Laboratories con-
sisted of 179 specimens with measurable HCV RNA by the
bDNA assay and 21 specimens without detectable HCV RNA
by the bDNA assay, with HCV genotypes 1a (n  65), 1b (n 
21), 2 (n  4), and 3 (n  7) determined for 97 of the HCV
RNA-positive specimens by the Trugene HCV 5NC genotyp-
ing kit (Trugene; Siemens Healthcare Diagnostics Inc.). The
110 sera collected at the Mayo Clinic included 100 specimens
with measurable HCV RNA by the bDNA assay and 10 HCV
RNA-negative specimens from healthy blood donors. These
100 HCV RNA-positive sera consisted of samples with HCV
genotypes 1 (n 25), 2 (n 25), 3 (n 20), 4 (n 20), 5 (n
5), and 6 (n  5), as determined by Trugene. All bDNA and
Trugene testing was performed according to the manufactur-
er’s instructions. The 156 specimens from Washington Univer-
sity School of Medicine consisted of 141 and 15 specimens with
and without detectable HCV RNA according to the TaqMan
assay, respectively. Among the 141 specimens with measurable
HCV RNA, 86 had HCV genotype determination performed
by the Versant HCV Genotype 2.0 assay (Siemens Healthcare
Diagnostics Inc.), following the manufacturer’s instructions,
which yielded HCV genotypes 1a (n 46), 1b (n 21), 1 (n
1), 2a/c (n  2), 2b (n  3), and 3a (n  13). The TaqMan
assay was performed with the Cobas TaqMan 48 analyzer
(Roche Molecular Systems, Inc.); sample preparation was
done by use of the QIAamp viral RNA minikit, and calibration
to OptiQuant HCV RNA quantification panels (AcroMetrix
Corp., Benicia, CA) was performed as previously described
(2, 14).
Initial testing of fivefold dilutions of the high-titer HCV-
positive serum specimen by the small-volume RTx protocol
yielded CT values below the established threshold in all 20
reactions for each dilution, except for the 3,125-fold dilution,
which showed acceptable CT values in only 10 reactions. When
calibrated to WHO Second International HCV standard 96/
798, the standard curve derived by least-squares regression
analysis of the CT and relative sample concentration (i.e., di-
lution factor) yielded a best-fit linear equation of CT3.8
log10 IU/ml  52.3 (r  0.984, PCR efficiency  83%). The
mean CT values SDs for detectable replicates of the 625- and
3,125-fold dilutions translated to 3.91  0.89 log10 IU/ml and
3.65  1.13 log10 IU/ml, respectively. Among HCV genotypes
FIG. 1. Linearity of the RTx assay. (A) The upper graph shows
real-time PCR fluorescence data as baseline-adjusted relative fluores-
cence units (RFU) versus the number of PCR cycles. The lower graph
shows Tm analysis of the negative value of the change in RFU over the
change in temperature (dRFU/dT) versus temperature (degrees Cel-
sius). (B) Linear relationship between RTx assay CT values and 3
UTR target copy numbers/reaction. Eff, efficiency.
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contained in the worldwide HCV performance panel, overall
mean VL differences  SDs between the small-volume RTx
assay and the bDNA assay and between the small-volume RTx
assay and CAM test were 0.08  0.19 log10 IU/ml (range,
0.22 to 0.46 log10 IU/ml) and 0.20  0.22 log10 IU/ml (range,
0.23 to 0.59 log10 IU/ml), respectively (Fig. 2).
Four of 277 clinical specimens that were previously tested by
the bDNA assay and had measurable HCV VLs by the bDNA
assay were negative for HCV RNA by the small-volume RTx
assay, while 2 specimens had VLs above the upper limit of
quantification by the bDNA assay. Supplemental testing of the
four specimens yielding qualitatively discordant results by the
qualitative large-volume RTx protocol resolved two of four
discordant results. However, the SPR failed to generate a
hexachlorofluorescein signal in the third specimen despite
multiple attempts with the large-volume RTx protocol (sug-
gesting the presence of PCR inhibitors), while the fourth spec-
imen was consistently negative by the large-volume RTx assay.
Linear regression analysis of paired results from 273 specimens
quantifiable by both the small-volume RTx assay and the
bDNA assay indicated a good correlation (r  0.95), with a
slope of 0.88 (Fig. 3A). A Bland-Altman plot of VL differences
between the small-volume RTx assay and the bDNA assay
yielded a mean difference of 0.48 log10 IU/ml, with 1.96 SD
limits at 0.51 log10 IU/ml and a range of 0.02 to 0.98 log10
IU/ml (Fig. 3B). Agreement between the small-volume RTx
assay and the bDNA assay improved with increasing VLs,
especially at concentrations of 5.0 log10 IU/ml. Specimens
containing HCV genotype 3 (n 27) yielded a mean difference
of 0.75 log10 IU/ml between the small-volume RTx assay and
the bDNA assay, compared to a mean difference of 0.48 log10
IU/ml for all 273 specimens. The difference in VLs between the
two assays for genotype 3 was statistically significant (P 0.005),
FIG. 2. Differences in HCV VL results with a worldwide HCV
performance panel of six HCV genotypes tested by three assay meth-
ods (F, small-volume RTx assay result  bDNA assay result; ,
small-volume RTx assay result  CAM test result). The dotted line
indicates the mean difference between small-volume RTx assay and
bDNA assay results, and the dashed line indicates the mean difference
between small-volume RTx assay and CAM test results.
FIG. 3. Comparisons of small-volume RTx assay results to bDNA and TaqMan results for clinical serum and plasma specimens for quantifi-
cation of HCV RNA. (A) Linear regression analysis of the small-volume RTx assay versus the bDNA assay for 273 specimens. (B) Bland-Altman
plot of paired VL differences between the small-volume RTx assay and the bDNA assay. (C) Linear regression analysis of the small-volume RTx
assay versus the TaqMan assay for 98 specimens. (D) Bland-Altman plot of paired VL differences between the small-volume RTx and TaqMan
assay VLs. HCV genotypes in panels B and D are indicated by the following symbols: F, genotype 1; ‚, genotype 2; E, genotype 3; , genotype
4; Œ, genotype 5; f, genotype 6; , genotype unspecified.
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while differences for genotypes 1, 2, 4, and 5 were insignificant
by one-way analysis of variance with Tukey-Kramer adjustment
for multiple comparisons. Comparison between genotypes 3
and 6 was inconclusive due to the small number of genotype 6
specimens in this study.
Small-volume RTx assay yielded measurable HCV VLs for
98 of 100 specimens with VLs of 3 log10 IU/ml by the Taq-
Man assay, but HCV RNA was detectable in only 4 of 41
specimens with TaqMan assay VLs of 3 log10 IU/ml. Suffi-
cient specimen volume was available for qualitative large-vol-
ume RTx assay testing of 13 of these 41 specimens, with HCV
RNA detected in 10 of 13 (77%) specimens. Linear regression
analysis of paired data from 98 specimens with HCV VLs of
3 log10 IU/ml by the TaqMan assay and measurable VLs by
both methods showed a good correlation (r  0.94), with a
slope of 0.86 (Fig. 3C). A Bland-Altman plot of VL differences
between the small-volume RTx assay and the TaqMan assay
for these 98 specimens yielded a mean difference of 0.10 log10
IU/ml, with 1.96 SD limits at 0.61 log10 IU/ml and a range
of 0.51 to 0.70 log10 IU/ml (Fig. 3D). Improved agreement
with increasing VLs between the small-volume RTx assay and
the TaqMan assay was also observed. Among specimens with
known HCV genotypes, 82 yielded measurable VLs by the small-
volume RTx assay, with a statistically significant (P 0.005) dif-
ference between the small-volume RTx assay and the TaqMan
assay VLs among specimens containing genotype 3 (as op-
posed to genotypes 1 and 2) (one-way analysis of variance with
Tukey-Kramer adjustment for multiple comparisons). There
were no false-positive results with the small-volume RTx pro-
tocol among the combined total of 46 HCV RNA-negative
specimens previously tested by the bDNA or TaqMan assay.
Analytical studies demonstrated that the RTx assay was ca-
pable of detecting HCV RNA present at a low copy number
(i.e., 50% detection at 10 copies/reaction), and the RTx assay
was linear over 7 orders of magnitude. However, the PCR
efficiency of 94% determined with a synthetic HCV 3 UTR
target was higher than the 83% efficiency seen with the small-
volume RTx protocol. While correlation between small-vol-
ume RTx and bDNA assay VLs was good, the sensitivity of the
small-volume RTx protocol did not compare well to that of the
TaqMan assay. The bias for VLs being higher with the small-
volume RTx assay than with the bDNA assay at5 log10 IU/ml
may be due to differences in calibration, a predominance of
specimens with VLs of 5 log10 IU/ml, or intrinsic perfor-
mance characteristics of the RTx assay.
These preliminary studies suggest that an RTx-based assay
targeting the HCV 3 UTR may be used for quantification of
HCV RNA in human serum or plasma. Despite the signifi-
cantly higher VL for HCV genotype 3 when the small-volume
RTx assay results were compared to the bDNA and TaqMan
assay results, further optimization of assay conditions, in-
creased sample input volume, and a more rigorous calibration
of the RTx assay should be capable of achieving the increased
sensitivity and accuracy necessary for detection and quantifi-
cation of HCV RNA to meet clinical needs (12).
We acknowledge the technical assistance of Katherine Cavaletti and
Magda Dwidar (Washington University Medical School, St. Louis,
MO) and statistical analyses by Jayawant N. Mandrekar (Mayo Clinic,
Rochester, MN).
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